Breaking Finance News

Zacks Investment Research upgraded Trinity Biotech plc (ADR) (NASDAQ:TRIB) to Hold in a statement released earlier today.

Having a price of $12.75, Trinity Biotech plc (ADR) (NASDAQ:TRIB) traded 0.32% higher on the day. With the last stock price up 7.86% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. TRIB has recorded a 50-day average of $12.81 and a two hundred day average of $11.76. Trade Volume was down over the average, with 46,017 shares of TRIB changing hands under the typical 52,898

Zacks Investment Research has upgraded Trinity Biotech plc (ADR) (NASDAQ:TRIB) to Hold in a statement released on 9/22/2016.

Recent Performance Chart

Trinity Biotech plc (ADR) (NASDAQ:TRIB)

Trinity Biotech plc (ADR) has PE ratio of 53.96 with a one year low of $9.20 and a one year high of $13.68 and has a market capitalization of $0.

General Company Details For Trinity Biotech plc (ADR) (NASDAQ:TRIB)

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business. Trinity Biotech's blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.